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NEUROLOGICAL MANIFESTATIONS
OF CELIAC DISEASE
José Ibiapina Siqueira Neto1, Ana Carolina Leite Vieira Costa2,
Francisco George Magalhães3, Gisele Sampaio Silva4
ABSTRACT - Celiac disease (CD/ Nontropicalsprue, gluten-sensitive enteropathy) is a malabsortive condi-
tion in which an allergic reaction to the cereal grain-protein gluten (present in wheat, rye and barley) caus-
es small intestine mucosal injury. The onset is in the first four decades of life, with a female to male ratio
of 2:1. It may be associated with a wide spectrum of neurological manifestations including cerebellar atax-
ia, epileptic seizures, dementia, neuropathy, myopathy and multifocal leucoencephalopathy. We report three
patients with neurological manifestations related with CD: one with cerebellar ataxia, one with epilepsy
and one with cognitive impairment. The diagnosis of CD was confirmed by serologic tests (antiendomysial
and antigliadin antibodies) and biopsy of the small intestine. In two patients the neurological symptoms
preceded the gastrointestinal abnormalities and in all of them gluten restriction failed to improve the neu-
rological disability. Conclusion: CD should be ruled out in the differential diagnosis of neurological dys-
function of unknown cause, including ataxia, epilepsy and dementia. A gluten free diet, the mainstay of
treatment, failed to improve the neurological disability.
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Manifestações neurológicas da doença celíaca
RESUMO - A doença celíaca (DC, enteropatia sensível ao glúten) é desordem caracterizada por mal absorção
causada por reação alérgica ao glúten, proteína presente em diversos cereais. As manifestações iniciais ocor-
rem nas primeiras quatro décadas de vida, sendo cerca de duas vezes mais freqüente no sexo feminino.
DC pode estar associada a largo espectro de manifestações neurológicas incluindo ataxia cerebelar, epilep-
sia, demência, neuropatia, miopatia e leucoencefalopatia multifocal. Relatamos três casos de pacientes com
manifestações neurológicas da DC: um com ataxia cerebelar, outro com epilepsia e o último com déficit
cognitivo. O diagnóstico de DC foi estabelecido com base em testes sorológicos (anticorpos antiendomí-
sio e antigliadina) e biópsia intestinal. Em dois pacientes as alterações neurológicas precederam as gas-
trointestinais. Em todos os casos a dieta livre de glúten não influenciou o quadro neurológico. Concluímos
que o diagnóstico de DC deve ser considerado em pacientes com alterações neurológicas de etiologia inde-
terminada, incluindo ataxia, epilepsia e demência. Uma dieta sem glúten, a base do tratamento das mani-
festações gastrointestinais, não foi eficiente em melhorar os sintomas neurológicos em nossos pacientes.
PALAVRAS-CHAVE: doença celíaca, ataxia cerebelar, epilepsia.
Celiac disease (CD) is an autoimmune disease of
the small intestine precipitated by the ingestion of
gluten in genetically susceptible individuals. The
true prevalence is difficult to ascertain since many
patients have atypical symptoms. Studies in both
Europe and North America estimate the seropreva-
lence to be 1 of every 120 to 300 persons1,2. The
symptoms of CD may appear with the introduction
of cereals in an infant’s diet or may first become
evident in adulthood. Classic signs are related to
the gastrointestinal tract. Extraintestinal manifesta-
tions include anemia, coagulopathy, metabolic bo-
ne diseases, infertility1, psychiatric syndromes3 and
various neurological disorders4. The diagnosis of
CD is based on serologic tests (antiendomysial, an-
tigliadin and antitransglutaminase antibodies) and
on characteristic histopathological changes (vil-
lous atrophy, crypt hyperplasia and inflammatory-
cell infiltrates) seen on distal duodenal biopsy, the
gold standard test.  Initiation of a gluten-free diet
rapidly reverses the mucosal lesion and corrects mal-
absorption with symptomatic improvement4,5.
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Neurological complications are estimated to oc-
cur in 6 to 10% of patients with CD5. Recently a high
proportion of patients with neurological symp-
toms of unknown origin were found to have glu-
ten sensitivity6. Cerebellar ataxia, epilepsy, neu-
ropathy, dementia and multifocal leucoencephalo-
pathy have all been described7-10. Only exception-
ally these syndromes improved with gluten restric-
tion4 and, in some patients, the neurological man-
ifestations even progress despite resolution of both
pathologic findings and intestinal symptoms4. 
We report three cases of patients with predom-
inant neurological symptoms who had a diagno-
sis of previously unsuspected CD.
CASES
Case 1 – A 40-year-old woman was admitted to the
hospital because of severe intention tremor and gait dis-
order that started four years ago. Routine blood examina-
tion revealed only a microcytic anemia and decreased
ceruloplasmin levels. Computed tomographic scan of the
brain was normal. The patient was treated with penicilla-
mine for Wilson’s disease. One year later, myoclonus
and dysarthria occurred. Some weeks afterwards, the
patient presented diarrhea and important weight loss.
The laboratory findings showed a slight reduction of se-
rum vitamin E, B12 and folic acid. Ceruloplasmin level
was normal. Tests for antiendomysium and IgA antig-
liadin were negative, but IgG antigliadin was highly po-
sitive. Sudam III and xylose tests showed malabsorp-
tion. A small intestine biopsy demonstrated the classic
histological lesion of untreated CD (villous atrophy, cry-
pt hyperplasia and inflammatory-cell infiltrates). The
patient was placed on a gluten-free diet with improve-
ment of the gastrointestinal symptoms. In the follow-
ing year, intention tremor, ataxic gait, myoclonus and
dysarthria were associated with terminal dysmetria, in-
ferior limbs paresis and incoordination. Magnetic reso-
nance imaging (MRI) of the brain demonstrated marked
cerebellar atrophy. Despite the normalization of vitamin
levels, the patient remains with neurological symptoms.
Case 2 – A 24 year-old woman was first seen in 1999
for epilepsy. She had had complex-partial crises for one
year. Her physical and neurological examinations were
unremarkable at that time. A MRI showed multiple whi-
te matter hyperintensities on T2-weighted images and
a left frontal lesion that enhanced after gadolinium ad-
ministration. She was treated for neurocysticercosis ba-
sed on serologic and cerebrospinal fluid reactions. Ox-
carbazepine was initiated. One year later, she devel-
oped inattention, learning difficulties and postural tre-
mors. At that time, she was using divalproate sodium
because of intolerance to oxcarbazepine. A MRI was re-
peated and showed a cicatricial left frontal lesion and
the same white matter abnormalities. Topiramate was
substituted for divalproate and the tremor and cogni-
tive symptoms improved, but did not resolve. She start-
ed loosing weight progressively and did not improve after
discontinuing topiramate. At that time, tests for antig-
liadin antibody were highly positive and a small intes-
tine biopsy showed important villous atrophy. She gained
weight with a gluten-free diet.  One year later, she dis-
continued the diet and persisted with mild cognitive
symptoms, but did not have epileptic crises again. 
Case 3 – A 45 year-old man was first seen in 2001 be-
cause of memory loss and inability to work for one year.
His neurological examination was unremarkable except
for a mini-mental examination (MME) of 22, an impor-
tant delay in answering simple questions and difficulty
in naming objects. He had a previous history of chron-
ic diarrhea that was never investigated. A high titer of
antiendomysium antibody was detected and a small
bowel biopsy showed inflammatory changes. Neuro-
cognitive evaluation revealed inattention, evocation
deficits, impaired verbal fluency and disturbed visual and
verbal memories. A brain MRI showed cortical and cere-
bellar atrophy (Fig1). He was placed on a gluten-free diet
and gastrointestinal symptoms resolved, but he persist-
ed with an important cognitive impairment. Eighteen
months later a new neuropsychological evaluation sho-
wed progression of the deficits. The patient is now sta-
ble with a new brain MRI similar to the previous one and
a MME of 25 obtained in his last visit.
DISCUSSION
Neurological disorders associated with gastroin-
testinal (GI), pancreatic, or liver diseases are poor-
Fig 1. Sagital T1-weighted scan showing important cortical
atrophy.
ly recognized. In consequence, their diagnosis and
treatment are often unnecessarily delayed. Ma-
labsorption is a word used to describe disorders in
which ingested nutrients are not completely ab-
sorbed. These conditions can cause neurological ab-
normalities both through specific nutritional defi-
ciencies and through multisystem involvement
associated with specific disorders11. The differen-
tial diagnosis of mucosal malabsorption disorders
is quite broad and include: CD, nongranulomatous
ulcerative jejunoileitis, eosinophilic gastroenteri-
tis, Crohn’s disease, radiation enteritis, immunopro-
liferative small intestinal disease and chronic me-
senteric ischemia12.
CD may present with numeral neurological ma-
nifestations even without clinical evident malab-
sorption of nutrients. Although neurological symp-
toms are rare in children, as many as 36 percent
of adult patients have been reported to have neu-
rological manifestations13. Cerebellar ataxia, de-
mentia and myoclonus make up the central nerv-
ous system manifestations of CD. The neuromuscu-
lar manifestations of CD include polymyositis, der-
matomyosistis and inclusion-body myositis4. 
The diagnostic test for celiac disease is a small
intestine biopsy that shows loss of vili and flatten-
ing of the mucosa, which in is formed of cuboidal
cells instead of the normal columnar cells. The
crypts are elongated and inflammatory cells can be
shown. The screening test for CD is the measure-
ment of circulating antigliadin, antiendomysial
and antitransglutaminase antibodies5.
It is well known that CD may be associated with
sporadic and hereditary ataxias8. Our first patient
has a six-year history of cerebellar ataxia. Only
one year after the presentation of the neurologi-
cal symptoms, she started to manifest gastrointesti-
nal complaints. 
Neuropathologic findings in autopsy of patients
with gluten ataxia showed perivascular cuffing with
inflammatory cells, predominantly affecting the
cerebellum, resulting in loss of Purkinje cells. This
suggests that the neurological insult may be immune
mediated14. Hadjivassiliou et al. showed that in
patients with gluten ataxia antigliadin antibodies
cross-react with epitopes on Purkinje cells15. Recently,
it has been suggested that both humoral and cell-
mediated responses play a part in the pathogene-
sis of gluten ataxia16. Gluten ataxia is primarily a slow-
ly progressive ataxia, and aggressive cerebellar
degeneration is the exception rather than the rule16.
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Epilepsy is another neurological complication of
CD17. Many authors described the association of ce-
rebral calcification, CD and seizures18. Although var-
ious hypotheses have been proposed, ranging from
free radical accumulation with oxidative stress to tox-
in deposition, the precise mechanisms for such asso-
ciation remains unknown. CD must be considered
in selected patients with medically refractory seizures
since potential alternative therapies can be helpful6.
Cross-sectional MRI characteristics have been report-
ed in a few cases of CD associated with neurologic
complications. The evolution of cerebral involvement
in the course of CD using serial MRIs was described
in a case of relapsing-progressive symptoms includ-
ing brainstem and cerebellar involvement. In this case
the multiple enhancing lesions on the first MRI
were favorably modified by steroid treatment, sug-
gesting the presence of an immunologic process19.
Our patient had a brain MRI that showed multiple
white matter hyperintensities on T2-weighted
images and a left frontal lesion that enhanced after
gadolinium administration. White matter abnor-
malities allows differential diagnosis with a wide
spectrum of disorders such as: multiple sclerosis,
cerebral vasculitis, neurosarcoidosis, Sjögren dis-
ease, infectious (Lyme and Whipple) and inherited
(adrenoleucodystrophy and metachromatic leu-
codysthrophy) disorders20.
Cognitive and psychiatric disturbances were
also described in patients with CD21. While the
burden of any chronic disease is sufficient to cause
a mood alteration, studies suggest a distinct pro-
file among patients with CD22. Pathophysiology
of such clinical signs remains to be determined, but
the role of an eventual tissue specific transglutami-
nase, like in dermatitis herpetiformis, may be sug-
gested. Vitamin B12 deficiency has been associat-
ed with hematological, neurological and psychiatric
symptoms. Although the terminal ileum is relative-
ly spared in CD, vitamin B12 deficiency is not unusu-
al in untreated CD patients. An immunologic etio-
logy can not be ruled out in patents with CD and
cognitive deficits21. A study including 33 Alzheimer’s
patients and 24 controls showed that the prevalen-
ce of CD in Alzheimer’s disease (AD) is not higher
than in cognitively unimpaired elders, suggesting
that the immune changes in CD are unlikely to play
a role in AD22.
Antigliadin antibodies have been found in the
cerebrospinal fluid in patients with gluten sensiti-
vity and neurological dysfunction23. Nevertheless,
these antibodies are present in almost all patients
with CD, but only a small proportion of them de-
velop neurological symptoms. One hypothesis may
be that antigliadin antibodies only become neuroto-
xic if they gain access to the central nervous system15. 
Our cases demonstrate that neurological symp-
toms may be the first manifestations of CD and may
not respond to or even progress during a gluten-
free diet. Accurate diagnosis of CD is challenging
because gastrointestinal symptoms may be entire-
ly absent or may be overshadowed by extraintesti-
nal complaints24. An increased prevalence of CD has
been reported in neurological disorders of unk-
nown etiology. A recent study showed that the fre-
quency of undiagnosed CD might be as high as 16%
in patients with neurological manifestations of
unknown origin8. Pathogenic mechanisms of neuro-
logical dysfunction in CD remain uncertain. Nowa-
days, the immune, rather than the nutritional chan-
ges of CD, are given more credit in the literature8,14.
In fact, neurological symptoms are found with or
without histologic evidence of CD, gastrointesti-
nal symptoms or malabsorption signs4.
The mucosal lesion and clinical gastrointestinal
symptoms recover on gluten-free diet1. However,
the effect of gluten elimination on neurological
manifestations is not very clear. The duration of glu-
ten exposure may be important, but the correla-
tion in a large series was not significant4. A long
diagnostic delay of CD or poor dietary compliance
may be harmful for the overall outcome and lead
to severe complications. This report emphasizes the
importance of investigating CD in patients with ne-
urological disorders of unknown origin.
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